Brief: Synlogic Granted FDA Fast Track Designation For SYNB1353 For The Treatment Of Homocystinuria
23/08/2022 12:55
Aug 23 (Reuters) - Synlogic Inc SYBX.O :
* SYNLOGIC GRANTED FDA FAST TRACK DESIGNATION FOR SYNB1353
FOR THE
TREATMENT OF HOMOCYSTINURIA (HCU)
* SYNLOGIC INC - SYNLOGIC EXPECTS TO SHARE RESULTS FROM
PHASE 1
STUDY OF SYNB1353 IN HEALTHY VOLUNTEERS BY END OF 2022
Source text for Eikon: ID:nGNX4tBmvb
Further company coverage: SYBX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Synlogic
See all newsBrief: Synlogic Receives Letter From Nasdaq Listing Qualifications Department On Nov 21 - SEC Filing
Brief: Synlogic Inc Files For Mixed Shelf Of Up To $150 Million – SEC Filing
Synlogic Inc reports results for the quarter ended September 30 - Earnings Summary
Synlogic Inc expected to post a loss of 10 cents a share - Earnings Preview
Synlogic Inc reports results for the quarter ended in January - Earnings Summary